The inactivated NDV-HXP-S COVID-19 vaccine induces a significantly higher ratio of neutralizing to non-neutralizing antibodies in humans as compared to mRNA vaccines

Juan Manuel Carreño¹, Ariel Raskin¹, Gagandeep Singh¹, Johnstone Tcheou¹, Hisaaki Kawabata¹, Charles Gleason¹, Komal Srivastava¹, Vladimir Vigdorovich², Nicholas Dambrauskas², Sneha Lata Gupta^{3,4}, Irene Gonzalez¹, Jose Luis Martinez¹, Stefan Slamanig¹, D. Noah Sather^{2,5}, Rama Raghunandan⁶, Ponthip Wirachwong⁷, Sant Muangnoicharoen⁸, Punnee Pitisuttithum⁸, Jens Wrämmert^{3,4}, Mehul S. Suthar^{3,4,9}, Weina Sun¹, Peter Palese^{1,10}, Adolfo García-Sastre^{1,10,11,12,13}, Viviana Simon^{1,10,11,13}, Florian Krammer^{1,13,*}

Rama Raghunandan, PhD PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA

¹Department of Microbiology, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA

²Center for Global Infectious Disease Research, Seattle Children's Research Institute, Seattle WA 98109 USA

³Centers for Childhood Infections and Vaccines, Children's Healthcare of Atlanta and Emory University, Department of Pediatrics, Atlanta, GA, 30329 USA

⁴Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA, 30329 USA

⁵Department of Pediatrics, University of Washington, Seattle WA 98109 USA

⁶PATH, 2201 Westlake Avenue, Suite 200, Seattle, WA 98121, USA

⁷The Government Pharmaceutical Organization, 1 Thanon Rama VI, Thung Phaya Thai, Ratchathewi, Bangkok 10400, Thailand

⁸Vaccine Trial Centre Faculty of Tropical Medicine, Mahidol, 420/6 Ratchawithi Road, Ratchathewi, Bangkok 10400, Thailand

⁹Department of Microbiology and Immunology, Emory University, Atlanta, GA, USA

¹⁰Division of Infectious Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA

¹¹Global Health and Emerging Pathogens Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA

¹²The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA

¹³Department of Pathology, Molecular and Cell based Medicine, Icahn School of Medicine at Mount Sinai, 1 Gustave L. Levy Pl, New York, NY 10029, USA

*To whom correspondence should be addressed: florian.krammer@mssm.edu

Abstract

NDV-HXP-S is a recombinant Newcastle disease virus based-vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which expresses an optimized (HexaPro) spike protein on its surface. The vaccine can be produced in embryonated chicken eggs using the same process as that employed for the production of influenza virus vaccines. Here we performed a secondary analysis of the antibody responses after vaccination with inactivated NDV-HXP-S in a Phase I clinical study in Thailand.

The SARS-CoV-2 neutralizing and spike binding activity of NDV-HXP-S post-vaccination serum samples was compared to that of matched samples from mRNA BNT162b2 (Pfizer) vaccinees. Neutralizing activity of sera from NDV-HXP-S vaccinees was comparable to that of individuals vaccinated with BNT162b2. Interestingly, the spike binding activity of the NDV-HXP-S vaccinee samples was lower than that of sera obtained from individuals vaccinated with the mRNA vaccine. This let us to calculate ratios between binding and neutralizing antibody titers. Samples from NDV-HXP-S vaccinees had binding to neutralizing activity ratios similar to those of convalescent sera suggesting a very high proportion of neutralizing antibodies and low non-neutralizing antibody titers. Further analysis showed that, in contrast to mRNA vaccination, which induces strong antibody titers to the receptor binding domain (RBD), the N-terminal domain, and the S2 domain, NDV-HXP-S vaccination induces a very RBD focused response with little reactivity to S2. This explains the high proportion of neutralizing antibodies since most neutralizing epitopes are located in the RBD. In conclusion, vaccination with inactivated NDV-HXP-S induces a high proportion of neutralizing antibodies and absolute neutralizing antibody titers comparable to those after mRNA vaccination.

Introduction

A large number of vaccines for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed and licensed (1). Nevertheless, there is a need for SARS-CoV-2 vaccines that can be produced at low cost locally in low- and middle-income countries (LMICs). The NDV-HXP-S vaccine (2) is based on a Newcastle disease virus (NDV) vector which presents a stabilized HexaPro (3) version of the spike protein on its surface. This vaccine can be manufactured like influenza virus vaccines at low cost in embryonated chicken eggs in facilities located globally, including in LMICs (2, 4-6). NDV-HXP-S can be used as live vaccine (2, 7, 8) or as an inactivated vaccine (2, 9). Clinical trials with a live version are ongoing in Mexico (NCT04871737) and the US (NCT05181709), while the inactivated vaccine is being tested in Vietnam (NCT04830800), Thailand (NCT04764422,) and Brazil (NCT04993209). Results from the initial Phase I trials are promising and Phase I data from Thailand with the inactivated vaccine have been reported (9). Phase II trials with the inactivated vaccine have also been successfully conducted, while Phase III trials are currently in the planning stage.

It has been shown that both natural infection- and vaccine-induced immunity target different parts of the SARS-CoV-2 spike protein, including the receptor binding domain (RBD), the N-terminal domain (NTD), and the S2 domain (10-15). Most described neutralizing epitopes can be found on the RBD and the NTD, while very few S2 directed antibodies neutralize the virus *in vitro* (12, 16, 17). Furthermore, it has been shown that the ratio of neutralizing to non-neutralizing antibodies differs between natural infection and mRNA vaccination (10, 15). While mRNA vaccination induces higher absolute neutralizing antibody titers in serum, infection induces a higher proportion of neutralizing antibodies. In other words, a large percentage of mRNA vaccine-induced antibodies bind spike but do not neutralize the virus, while this percentage is lower after natural infection. In addition, it is known that, while neutralizing activity can be drastically reduced against viral variants, binding activity is better retained (18, 19). In this case, of course, the ratio between neutralizing and non-neutralizing antibodies also changes. While both neutralizing and binding antibodies have been implicated as correlates of protection (20), only neutralizing antibodies are likely to block infection.

Here we performed a secondary analysis comparing sera from individuals vaccinated with NDV-HXP-S in Thailand to sera from convalescent and mRNA vaccinated individuals collected under observational cohort

studies in New York City (e.g., PARIS study (21)) to investigate neutralizing activity, ratios of binding to neutralizing antibodies and activity against variants of concern.

Results

Serum samples from vaccinees and convalescent individuals

Two sets of sera were used for this study. The first set comprised of sera from a clinical trial in Thailand (NCT04764422) (9) which included six groups: a placebo control group (n=35), a group that received 1µg of inactivated NDV-HXP-S (n=35), a group that received 1µg plus ODN1018 adjuvant (n=35), a group that received 3µg (n=35), a group that received 3 µg plus ODN1018 (n=35) and a group that received 10µg of NDV-HXP-S (n=35). Individuals were vaccinated twice, on day 1 and day 29; sera tested were collected two weeks after the boost (day 43). The second set of sera were from observational longitudinal studies conducted in New York City and comprised of serum samples from 20 study participants (PARIS) who received the BNT162b2 (Pfizer) mRNA vaccine and 18 serum samples from convalescent individuals (infected with prototype SARS-CoV-2; PARIS as well as viral infection cohorts). Sera were collected approximately 14 days post 2nd dose for the BNT162b2 vaccinees and approximately four weeks post infection for convalescent individuals. Age ranges and sex distribution between the samples from Thailand and New York were comparable (Table 1).

Neutralizing activity against wild type SARS-CoV-2 of sera from NDV-HXP-S vaccinees is similar to that of sera from BNT162b2 vaccinees

First, we tested the neutralizing activity of the sera from the NDV-HXP-S trial (placebo, 1µg, 1 µg + ODN1018, 3µg, 3µg + ODN1018, and 10µg) as well as the BNT162b2 and the human convalescent sera (HCS) against wild type SARS-CoV-2. Few individuals in the placebo control group had detectable neutralizing activity (8/35), and those who were positive had a low titer resulting in a 50% inhibitory dilution (ID₅₀) geometric mean titer (GMT) of 1:5.9 (Figure 1A). NDV-HXP-S ID₅₀ titers ranged from 1:73.4 (1µg) to 1:231.1 (10µg). A difference between adjuvanted and nonadjuvanted formulations was only found for the 3µg dose with 1:123.0 and 1:101.1 GMT, respectively. BNT162b2 recipient sera had a GMT of 1:146.8, whereas the HCS had a GMT of 1:68.0. While these differences were large, no statistical significance between the groups could be established in a one-way ANOVA when corrected for multiple comparisons due to small group size. Similar activity was detected against the B.1.617.2 (Delta) and B.1.351 (Beta) variants, although – as expected – with reduced titers (Figure 1B and C).

Binding activity of sera from NDV-HXP-S vaccinees is lower than that of sera from BNT162b2 vaccinees

Next, we assessed binding to wild type spike protein using the commercial SeroKlir Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit (22). Interestingly, binding antibody titers were much lower in this binding assay for the NDV-HXP-S vaccinees as compared to the BNT162b2 vaccinees (Figure 2A). Furthermore, the 10µg group was on par with the HCS group while other vaccine groups were slightly lower than the convalescents. To confirm these findings, we also tested binding to wild type spike in a research grade enzyme linked immunosorbent assay (ELISA) (23) (Figure 2B). Similar to what we observed in the Kantaro assay, the NDV-HXP-S vaccine induced decreased binding titers against wild type full-length spike compared to the BNT162b2 vaccine (Figure 2B). We also tested binding to an extensive array of variant spike proteins (Figure 2B). While binding was maintained across all variants tested, this pattern of lower binding activity of sera from NDV-HXP-S vaccinees was seen across the board.

The NDV-HXP-S vaccine induces an antibody response that consists of a high proportion of neutralizing antibodies

Since the neutralizing antibody titers of sera from NDV-HXP-S and BNT162b2 vaccinees were similar, and binding titers were much lower for NDV-HXP-S, we decided to determine ratios between binding and neutralizing titers (binding titers taken from **Figure 2B**, neutralizing titers taken from **Figure 1A**). As observed before (10, 15), the ratio of binding to neutralizing antibodies was much better (lower, indicating a higher proportion of neutralizing antibodies) in convalescent individuals as compared to individuals vaccinated with BNT162b2 (**Figure 3**). Surprisingly, the ratio of binding to neutralizing antibodies in NDV-HXP-S vaccinated individuals was similar to or even better than that of convalescent individuals, suggesting that a large proportion of the antibodies induced by this vaccine had neutralizing activity. To confirm these findings, randomly selected samples from the complete sample set were sent to an independent laboratory (the Suthar laboratory at Emory University) for validation of our findings. The laboratory was asked to measure binding and neutralization activities but the provided samples were blinded, and the reason for running the samples was not disclosed. The neutralization assay used in this second laboratory consisted of a focus reduction neutralization assay (FRNT), and the binding assay used was based on the MesoScale Discovery platform, in contrast to the microneutralization assay and ELISA used at Mount Sinai. While the ratios themselves were different (as to be expected due to the different methods used), the difference between convalescent sera and sera from mRNA vaccinated individuals was maintained (**Figure 3B**). Sera from NDV-HXP-S vaccinated individuals again showed ratios similar to sera from convalescent individuals. We also assessed these ratios for the Delta and Beta variants since both specific neutralizing activity and binding to the respective variant spikes were available. The pattern seen with wild type SARS-CoV-2 was also observed with these two viral variants (**Figure 3C and D**). Importantly, the ratios of binding to neutralizing activities in sera from BNT162b2 vaccinated individuals were significantly different from ratios measured in sera from NDV-HXP-S vaccinated or from convalescent individuals.

NDV-HXP-S drives an RBD focused immune response with little NTD and S2 antibodies induced

To determine which domains of the spike protein are targeted in convalescent, BNT162b2 mRNA vaccinated, and NDV-HXP-S vaccinated individuals we then performed ELISAs against recombinant RBD, NTD, and S2 proteins. Sera from all NDV-HXP-S vaccine regimens as well as BNT162b2 vaccination and natural infection, displayed strong RBD titers, albeit at different magnitudes (**Figure 4A**). NTD antibodies were predominantly only present at high titers in BNT162b2 vaccinated individuals (**Figure 4B**). Finally, S2 antibodies were strongly induced by natural infection and by BNT162b2 vaccination but to a much lower degree by NDV-HXP-S vaccination (**Figure 4C**). These data suggest that the strong neutralizing activity after NDV-HXP-S vaccination is likely driven by an RBD-focused response.

Discussion

During the COVID-19 pandemic, global vaccine distribution and vaccine equity were, and continue to be, suboptimal. Locally produced vaccines can increase vaccine access and vaccine independence, especially for LMICs. The NDV-HXP-S vaccine is designed to help close this gap since it can be economically produced in influenza vaccine manufacturing plants that are located in LMICs. Moreover, it can be stored and distributed without the need for freezers and incorporates an advanced HexaPro antigen design compared to most other COVID-19 vaccines on the market (3). The NDV-HXP-S vaccine development program also provides a vaccine platform and model that can be used for optimal pandemic preparedness

and response in LMICs in the future. Importantly, here we show that an inactivated version of the NDV-HXP-S vaccine is capable of inducing neutralizing antibody titers in humans that are comparable to titers induced by the BNT162b2 mRNA vaccine (Pfizer). Interestingly, while the induced neutralizing activity is comparable with mRNA vaccination, the binding antibody titers are much lower. This results in a response dominated by neutralizing antibodies, as observed when comparing ratios of binding to neutralizing antibody titers. It has been shown previously by our team and others, that mRNA vaccination – while inducing very high and protective neutralizing antibody titers – also induces a large quantity of non-neutralizing antibodies that, on a monoclonal level, target RBD, NTD, and S2 (10, 15). In fact, while neutralizing titers after natural infection are usually lower than after mRNA vaccination, the ratio of binding to neutralizing antibodies is more favorable. Here, we observe comparable ratios for convalescent individuals and NDV-HXP-S vaccinated individuals, while the ratios for mRNA vaccinees are significantly different. We confirmed these findings by using two different assay formats conducted in independent research laboratories for measuring both binding and neutralization activity. When analyzing the polyclonal response for binding to RBD, NTD, and S2, we found that mRNA vaccination induces strong immune responses against all three targets; natural infection mostly targets RBD and S2, while NDV-HXP-S targets almost exclusively the RBD. This explains the high proportion of neutralizing antibodies since most epitopes targeted by neutralizing antibodies are located in the RBD. There could be two reasons for this very focused immune response. First, presentation of the spike on the NDV particle could limit access of B-cell receptors to the extreme membrane distal part of the spike protein – which is the RBD. Akin to a dense forest of mature trees, the NDV-HXP-S particles are likely densely packed with NDV hemagglutinin-neuraminidase (HN), NDV fusion protein (F), and SARS-CoV-2 spike protein. It is easy to imagine, that B-cell receptors, which are also surrounded by many other membrane proteins on the surface of B-cells, could be sterically hindered from reaching the membrane proximal S2 domain or the NTD, which is also located closer to the membrane than the RBD. The second hypothesis is, that the HexaPro antigen design (3), which arrests the spike protein in the pre-fusion conformation, leads to a refocusing of the antibody response to the RBD. Many S2 epitopes may only be accessible in the post-fusion conformation and may be exposed in wild type spike or the metastable (2P) spike included in mRNA vaccines. These S2 epitopes may distract the immune responses from the RBD. A pre-fusion stabilized spike like the HexaPro may not display these epitopes, hence focusing most of the immune response to the RBD. Of course, the effect observed could also be caused by a combination of both mechanisms.

Our study has several limitations. We include a limited number of samples, and our dataset comes from a comparison of imperfectly matched groups from a clinical trial in Thailand and an observational cohort study in New York City. Strengths of the study include the use of authentic SARS-CoV-2 for neutralization assays and that the findings could be replicated with different methods in a different, blinded, and independent laboratory.

In summary, we show that a vaccine candidate which can be produced locally in LMICs at low cost induces neutralizing antibody titers to SARS-CoV-2 comparable to those observed in cohorts having received mRNA-based COVID-19 vaccines. The NDV-HXP-S vaccine candidate induces a strong RBD focused immune response resulting in a high proportion of neutralizing antibodies, which are associated with protection from infection and severe disease (20, 24, 25).

Methods

Human Serum Samples. Sera collected from the NDV-HXP-S clinical trial in Thailand (placebo, 1µg, 1 µg + ODN1018, 3µg, 3µg + ODN1018, and 10µg, n=35 samples per group) were used in this study. Characteristics of the clinical trial samples are indicated in **Table 1**. Additional detail can be found in the published interim report (9). In addition, we selected convalescent (n=18) and post-vaccine sera (n=20) that were collected from participants in two longitudinal observational studies. The BNT162b2 vaccinees were selected from the PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) cohort (21), while the convalescent serum samples were selected from PARIS as well as from our observational virus infection cohort to best match the demographics of the vaccine trial participants. The PARIS cohort follows health care workers of the Mount Sinai Health System longitudinally since April 2020 while the observational virus infection cohort is open to anyone willing to participate. These studies were reviewed and approved by the Mount Sinai Hospital Institutional Review Board (IRB-20-03374, IRB-16-00791). All participants signed written consent forms prior to sample and data collection. All participants provided permission for sample banking and sharing. All samples were stripped of identifying information before distribution to the participating laboratories.

Cells: Vero.E6 cells were cultured in Dulbecco's modified Eagles medium (DMEM) containing 10% heat-inactivated fetal bovine serum (FBS), supplemented with 100 U/ml penicillin and 100 µg/ml streptomycin (Gibco).

Recombinant variant RBD, NTD, S2 and spike proteins. The recombinant RBD and spike proteins used in Figure 2B (Wuhan-1, B.1.1.7) and Figure 4A were produced using Expi293F cells (Life Technologies). The sequences for the proteins were cloned into a mammalian expression vector, pCAGGS, as previously described and proteins were purified after transient transfections with each respective plasmid (23, 26). Six hundred million Expi293F cells were transfected using the ExpiFectamine 293 Transfection Kit and purified DNA. Supernatants were collected on day four post-transfection, centrifuged at 4,000 g for 20 minutes, and filtered using a 0.22 µm filter. Ni-nitrilotriacetic acid (Ni-NTA) agarose (Qiagen) was used to purify the proteins by gravity flow. The proteins were eluted as previously described. Buffer exchange was performed using Amicon centrifugal units (EMD Millipore), and all recombinant proteins were re-suspended in phosphate-buffered saline (PBS). Proteins were run on sodium dodecyl sulphate (SDS) polyacrylamide gels (5–20% gradient; Bio-Rad) to check for purity. NTD (Catalogue # 40591-V49H) and S2 (Catalogue #40590-V08B) recombinant proteins were acquired from Sino Biological.

Trimeric spike proteins in Figure 2B (all except Wuhan-1 and B.1.1.7) were produced as previously described (27). Briefly, residues 1-1208 of the spike protein (Wuhan-1 strain numbering) were codon optimized with proline substitutions at residues 986 and 987, the furin cleavage site modified to "GSAS", and a T4 fibritin trimerization motif and a 8X HIS tag were added on the C-terminus and the construct was cloned into pCDNA3.4. 293F cells were transfected with plasmid using PEI Max in FreeStyle 293 Expression Medium (Fisher) and cultured for three days at 32°C, 5% CO₂. Trimers were purified by Ni-NTA ion exchange chromatography followed by size exclusion chromatography on a HiLoad 16/60 Superdex 200 prep grade size exclusion column (GE Healthcare), and then were buffer exchanged into HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid)-buffered-saline with 10mM ethylenediaminetetraacetic acid (EDTA). Antigenicity was verified by ELISA and Octet bilayer interferometry. To create variants of concern, the designated amino acid substitutions corresponding to each variant were introduced into the Wuhan-1 sequence and purified as described above.

250

251 **In-house enzyme-linked immunosorbent assay (ELISA).** Antibody titers in sera were assessed using a
252 research-grade ELISA (23) with recombinant versions of the RBD, NTD, S2, and full-length spike of wild
253 type SARS-CoV-2, as well as the spike from B.1.1.7 (Alpha), C.37 (Lambda), B.1.617.1 (Kappa), B.1.351
254 (Beta), P.1 (Gamma), B.1.617.2 (Delta), A.23.1 and P.3. Briefly, 96-well microtiter plates (Corning) were
255 coated with 50 µl/well of the corresponding recombinant protein (2 µg/ml) overnight at 4 °C. After three
256 washes with phosphate-buffered saline (PBS) supplemented with 0.1% Tween-20 (PBS-T) using an
257 automatic plate washer (BioTek 405TS microplate washer), plates were blocked with PBS-T containing 3%
258 milk powder (American Bio) for one hour at room temperature (RT). Blocking solution was removed and
259 initial dilutions (1:100) of heat-inactivated sera (in PBS-T 1%-milk powder) were added to the plates,
260 followed by 2-fold serial dilutions and a two hour incubation. After three washes with PBS-T, 50 µl/well of
261 the pre-diluted secondary anti-human IgG (Fab-specific) horseradish peroxidase antibody (produced in
262 goat; Sigma-Aldrich) diluted 1:3,000 in PBS-T containing 1% milk powder were added and plates were
263 incubated for one hour incubation at RT. After three washes with PBS-T, the substrate o-
264 phenylenediamine dihydrochloride (Sigmafast OPD) was added (100 µl/well) for 10min, followed by an
265 addition of 50 µl/well of 3 M hydrochloric acid (Thermo Fisher) to stop the reaction. Optical density was
266 measured at a wavelength of 490 nm using a plate reader (BioTek, SYNERGY H1 microplate reader). Area
267 under the curve (AUC) values were calculated and plotted using Prism 9 software (GraphPad).

268 **Kantaro enzyme linked immunosorbent assay (ELISA).** Antibody testing with the commercial COVID-
269 SeroKlir Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit (Kantaro Biosciences, R&D Systems®
270 Catalog Number COV219) was performed as previously described (22). This assay has an approximate 99%
271 positive percent agreement and 99% negative percent agreement in PCR+ subjects 15 days post-symptom
272 onset
273 ([https://resources.rndsystems.com/pdfs/datasheets/cov219.pdf?v=20210525&_ga=2.12000950.307497](https://resources.rndsystems.com/pdfs/datasheets/cov219.pdf?v=20210525&_ga=2.12000950.307497989.1621962942-1278575996.1621962942)
274 [989.1621962942-1278575996.1621962942](https://resources.rndsystems.com/pdfs/datasheets/cov219.pdf?v=20210525&_ga=2.12000950.307497989.1621962942-1278575996.1621962942)). All reagents and microplates are included with the
275 commercial kit. Briefly, for qualitative RBD ELISAs, samples were diluted in sample buffer (1:100) using
276 96-well microtiter plates, and 100µl/well of pre-diluted samples were transferred to the RBD pre-coated
277 microplates. Positive and negative controls were added to every plate. Samples were incubated for 2
278 hours at room temperature. Serum dilutions were removed and plates were washed three times with the
279 included washing buffer. RBD conjugate was diluted in conjugate buffer and 100µl/well were added to
280 the plates for 1 hour. Conjugate was removed and plates were washed three times with wash buffer. To
281 develop the colorimetric reaction, the substrate solution was added (100µl/well) for 20min. 100µl/well of
282 stop solution were added, and plates were read at an optical density (OD) of 450nm and at an OD of
283 570nm for wavelength correction. As per the manufacturer's instructions, the cutoff index (CI) was
284 calculated by dividing the corrected OD of the clinical sample by the corrected OD of RBD positive control.
285 Samples with a CI above 0.7 were considered as presumptive positives and were further tested in the
286 confirmatory quantitative ELISA based on the full-length recombinant spike protein.

287 For the confirmatory quantitative spike ELISA samples were pre-diluted to 1:200 in sample buffer. Sample
288 dilutions were added in duplicate to the pre-coated microplates. Low, medium, and high controls, and
289 spike calibrators used to generate a standard curve, were added to every microtiter plate. After 2 hours
290 of incubation at room temperature, the remaining steps of the ELISA were performed as described above.
291 Data were analyzed using GraphPad Prism 9. The concentration of spike-reactive antibodies was
292 calculated using a four parameter logistic (4-PL) curve-fit. Samples exceeding the range of the standard

curve were further diluted and re-tested. Only samples positive in both steps of the assay were considered positive.

SARS-CoV-2 multi-cycle microneutralization assay. All procedures were performed in the Biosafety Level 3 (BSL-3) facility at the Icahn School of Medicine at Mount Sinai following standard safety guidelines. Vero.E6 cells were seeded in 96-well high binding cell culture plates (Costar) at a density of 20,000 cells/well in complete Dulbecco's modified Eagle medium (cDMEM) a day before infection. Heat inactivated sera (56°C for 1 hour) were serially diluted (3-fold) in minimum essential media (MEM; Gibco) supplemented with 2mM L-glutamine (Gibco), 0.1% sodium bicarbonate (w/v, HyClone), 10mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES; Gibco), 100U/ml penicillin, 100 µg/ml streptomycin (Gibco) and 0.2% bovine serum albumin (MP Biomedicals) starting at a 1:10 dilution. Remdesivir (Medkoo Bioscience inc.) was included as a control to monitor assay variation. Serially diluted sera were incubated with 1,000 tissue culture infectious dose 50 (TCID₅₀) of wild type USA-WA1/2020 SARS-CoV-2, B.1.617.2 (Delta) or B.1.351 (Beta) virus isolates for one hour at RT, followed by the transfer of 120µl of the virus-sera mix to Vero.E6 plates. Infection was left to proceed for one hour at 37°C, followed by removal of the inoculum. 100µl/well of the infection media supplemented with 2% fetal bovine serum (FBS; Gibco) and 100µl/well of antibody dilutions were added to the cells. Plates were incubated for 48 hours at 37°C and cell monolayers were fixed with 200µl/well of a 10% formaldehyde solution overnight at 4°C. After removal of the formaldehyde solution, and washing with PBS (pH 7.4) (Gibco), cells were permeabilized by adding 150µl/well of PBS, 0.1% Triton X-100 (Fisher Bioreagents) for 15 min at RT to allow staining of the nucleoprotein (NP). Permeabilization solution was removed and plates were blocked with PBS 3% BSA for 1 hour at RT. The biotinylated mAb 1C7C7, a mouse anti-SARS nucleoprotein monoclonal antibody generated at the Center for Therapeutic Antibody Development at the Icahn School of Medicine at Mount Sinai ISMMS (Millipore Sigma), was used for NP staining at a concentration of 1µg/ml in PBS, 1% BSA. After a 1 hour incubation at RT, cells were washed with 200µl/well of PBS twice and 100µl/well of HRP-conjugated streptavidin (Thermo Fisher Scientific) diluted in PBS, 1% BSA was added at a 1:2,000 dilution. Following a 1 hour incubation at RT, cells were washed twice with PBS, and 100µl/well of Sigmafast OPD were added for 10min at RT. Addition of 50µl/well of a 3M HCl solution (Thermo Fisher Scientific) allowed to stop the reaction. The optical density (OD) was measured (490 nm) using a microplate reader (Synergy H1; Biotek). All the analyses were performed using Prism 7 software (GraphPad). A nonlinear regression curve fit analysis was performed to calculate the inhibitory dilution 50% (ID₅₀).

Focus reduction neutralization test. FRNT assays were performed as previously described (28-30). Briefly, samples were diluted at 3-fold in 8 serial dilutions using DMEM (VWR, #45000-304) in duplicates with an initial dilution of 1:10 in a total volume of 60 µl. Serially diluted samples were incubated with an equal volume of icSARS-CoV-2 (100-200 foci per well based on the target cell) at 37° C for 45 minutes in a round-bottomed 96-well culture plate. The antibody-virus mixture was then added to Vero.E6-TMPRSS2 cells and incubated at 37°C for 1 hour. Post-incubation, the antibody-virus mixture was removed and 100 µl of pre-warmed 0.85% methylcellulose (Sigma-Aldrich, #M0512-250G) overlay was added to each well. Plates were incubated at 37° C for 18 hours and the methylcellulose overlay was removed and washed six times with PBS. Cells were fixed with 2% paraformaldehyde in PBS for 30 minutes. Following fixation, plates were washed twice with PBS and permeabilization buffer (0.1% BSA [VWR, #0332], saponin [Sigma, 47036-250G-F] in PBS) was added to permeabilized cells for at least 20 minutes. Cells were incubated with an anti-SARS-CoV spike primary antibody directly conjugated to Alexafluor-647 (CR3022-AF647) for up to 4 hours at room temperature. Cells were washed three times in PBS and foci were visualized on a CTL

Analyzer. Antibody neutralization was quantified by counting the number of foci for each sample using the Viridot program (31). The neutralization titers were calculated as follows: 1 - (ratio of the mean number of foci in the presence of sera and foci at the highest dilution of respective sera sample). Each specimen was tested in duplicate. The FRNT₅₀ titers were interpolated using a 4-parameter nonlinear regression in GraphPad Prism 9.2.0. Samples that do not neutralize at the limit of detection at 50% were plotted at 10 for geometric mean and fold-change calculations.

Multiplex Immunoassay. Serum samples were tested for their IgG binding against the SARS-CoV-2 Wuhan-1 strain using an electro chemiluminescent-based multiplex immunoassay provided by Mesoscale Discovery (MSD-ELICA). The experiment was performed according to the manufacturer's instructions. The COVID-19 Coronavirus Panel 1 (Catalog No. K15362U) was used for measuring spike antibody binding titers. Plates were pre-coated with the antigens. Briefly, blocking was performed for minimum of 30 min, with 150 µL per well of MSD Blocker A. To assess binding, samples were diluted 1:5000. 50 µL of each sample and Reference Standard dilution were added to the plates in duplicate and incubated for 2 hours. Following this, 50 µL per well of 1X MSD SULFO-TAG Anti-Human IgG detection antibodies were added and incubated for 1 hour. Following the detection reagent step, 150 µL per well of MSD Gold Read Buffer B was added to each plate immediately prior to reading on an MSD plate reader (MESO QuickPlex SQ 120). Plates were washed three times with 300 µL PBS/0.05% Tween 20 between each step. At every incubation step, plates were kept at RT and shaking with at a speed of 700 rpm. Data was analyzed using Discovery Workbench software. The antibody concentration in arbitrary units (AU) was calculated relative to the provided Reference Standard.

Statistics: A one-way ANOVA with correction for multiple comparisons test was used to compare the neutralization titers and ratios. In some cases, two groups were compared using a Student's t-test. Statistical analyses were performed using Prism 9 software (GraphPad).

Data availability statement

All data produced in the present study are available upon reasonable request to the authors.

Acknowledgments

We thank the study participants of the vaccine trial, the PARIS cohort and our longitudinal observational cohort for their generosity and willingness to help advance our knowledge on SARS-CoV-2 immune responses. We thank Dr. Randy A. Albrecht for oversight of the conventional BSL3 biocontainment facility at Mount Sinai, which makes our work with live SARS-CoV-2 possible. We are also grateful for Mount Sinai's leadership during the COVID-19 pandemic. We want to especially thank Drs. Dennis Charney, David Reich, and Kenneth Davis for their support. We also would like to thank the teams at PATH, Mahidol University and the Government Pharmaceutical Organization for their support.

This work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. In addition, this work was also partially funded by the NIAID Centers of Excellence for Influenza Research and Response (CEIRR) contract and 75N93021C00014 and 75N93021C00017 and by anonymous donations to Mount Sinai. Work on NDV-HXP-S vaccines was also supported by the Bill & Melinda Gates Foundation and by institutional funding from the Icahn School of Medicine at Mount Sinai. PATH funded the shipment of samples from Nexelis to Mount Sinai. The main NDV-HXP-S project in Thailand is funded by the National Vaccine Institute, Government Pharmaceutical Organization.

Conflict of interest statement

The vaccine administered in this study was developed by faculty members at the Icahn School of Medicine at Mount Sinai including FK, AGS, PP, and WS. Mount Sinai is seeking to commercialize this vaccine; therefore, the institution and its faculty inventors could benefit financially. The Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays (U.S. Provisional Application Numbers: 62/994,252, 63/018,457, 63/020,503 and 63/024,436) and NDV-based SARS-CoV-2 vaccines (U.S. Provisional Application Number: 63/251,020) which list FK as co-inventor. VS is also listed on the serological assay patent application as co-inventor. Patent applications were submitted by the Icahn School of Medicine at Mount Sinai. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. FK has consulted for Merck, Seqirus, Curevac and Pfizer, and is currently consulting for Pfizer, Third Rock Ventures, Merck and Avimex. The FK laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2. MSS serves in an advisory role for Ocugen and Moderna. The AGS laboratory has received research support from Pfizer, Senhwa Biosciences, Kenall Manufacturing, Avimex, Johnson & Johnson, Dynavax, 7Hills Pharma, Pharmamar, ImmunityBio, Accurius, Nanocomposix, Hexamer, N-fold LLC, Model Medicines, Atea Pharma and Merck, AGS has consulting agreements for the following companies involving cash and/or stock: Vivaldi Biosciences, Contrafect, 7Hills Pharma, Avimex, Vaxalto, Pagoda, Accurius, Esperovax, Farmak, Applied Biological Laboratories, Pharmamar, Paratus, CureLab Oncology, CureLab Veterinary and Pfizer, AGS is inventor on patents and patent applications on the use of antivirals and vaccines for the treatment and prevention of virus infections and cancer, owned by the Icahn School of Medicine at Mount Sinai, New York. PW is an employee of the Government Pharmaceutical Organization (GPO), who is the sponsor of the clinical trial and responsible for provisioning the investigational product used in clinical trial.

References

1. F. Krammer, SARS-CoV-2 vaccines in development. *Nature* **586**, 516-527 (2020).
2. W. Sun *et al.*, A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. *Nat Commun* **12**, 6197 (2021).
3. C. L. Hsieh *et al.*, Structure-based design of prefusion-stabilized SARS-CoV-2 spikes. *Science*, (2020).
4. E. Sparrow *et al.*, Global production capacity of seasonal and pandemic influenza vaccines in 2019. *Vaccine* **39**, 512-520 (2021).
5. W. Sun *et al.*, A Newcastle Disease Virus (NDV) Expressing a Membrane-Anchored Spike as a Cost-Effective Inactivated SARS-CoV-2 Vaccine. *Vaccines (Basel)* **8**, (2020).
6. W. Sun *et al.*, Newcastle disease virus (NDV) expressing the spike protein of SARS-CoV-2 as a live virus vaccine candidate. *EBioMedicine* **62**, 103132 (2020).
7. J. Tcheou *et al.*, Safety and Immunogenicity Analysis of a Newcastle Disease Virus (NDV-HXP-S) Expressing the Spike Protein of SARS-CoV-2 in Sprague Dawley Rats. *Front Immunol* **12**, 791764 (2021).
8. J. H. Lara-Puente *et al.*, Safety and Immunogenicity of a Newcastle Disease Virus Vector-Based SARS-CoV-2 Vaccine Candidate, AVX/COVID-12-HEXAPRO (Patria), in Pigs. *mBio*, e0190821 (2021).

9. P. Pitisuttithum *et al.*, Safety and Immunogenicity of an Inactivated Recombinant Newcastle Disease Virus Vaccine Expressing SARS-CoV-2 Spike: Interim Results of a Randomised, Placebo-Controlled, Phase 1/2 Trial. *medRxiv*, (2021).
10. F. Amanat *et al.*, SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell* **184**, 3936-3948.e3910 (2021).
11. G. Cerutti *et al.*, Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite. *Cell Host Microbe* **29**, 819-833.e817 (2021).
12. M. F. Jennewein *et al.*, Isolation and characterization of cross-neutralizing coronavirus antibodies from COVID-19+ subjects. *Cell Rep* **36**, 109353 (2021).
13. M. McCallum *et al.*, N-terminal domain antigenic mapping reveals a site of vulnerability for SARS-CoV-2. *Cell*, (2021).
14. C. Gaebler *et al.*, Evolution of Antibody Immunity to SARS-CoV-2. *bioRxiv*, (2020).
15. A. Cho *et al.*, Anti-SARS-CoV-2 receptor-binding domain antibody evolution after mRNA vaccination. *Nature* **600**, 517-522 (2021).
16. D. Pinto *et al.*, Broad betacoronavirus neutralization by a stem helix-specific human antibody. *Science* **373**, 1109-1116 (2021).
17. F. Amanat *et al.*, SARS-CoV-2 mRNA vaccination induces functionally diverse antibodies to NTD, RBD, and S2. *Cell*, (2021).
18. J. M. Carreño *et al.*, Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients. *EBioMedicine* **73**, 103626 (2021).
19. J. M. Carreño *et al.*, Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron. *Nature*, (2021).
20. K. A. Earle *et al.*, Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine*, (2021).
21. F. Krammer *et al.*, Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine. *N Engl J Med* **384**, 1372-1374 (2021).
22. J. M. Carreño *et al.*, Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms. *iScience* **24**, 102937 (2021).
23. D. Stadlbauer *et al.*, SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. *Curr Protoc Microbiol* **57**, e100 (2020).
24. P. B. Gilbert *et al.*, Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. *Science*, eab3435 (2021).
25. D. S. Khoury *et al.*, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med*, (2021).
26. F. Amanat *et al.*, A serological assay to detect SARS-CoV-2 seroconversion in humans. *Nat Med*, (2020).
27. W. E. Harrington *et al.*, Rapid decline of neutralizing antibodies is associated with decay of IgM in adults recovered from mild COVID-19. *Cell Rep Med* **2**, 100253 (2021).
28. A. Vanderheiden *et al.*, Development of a Rapid Focus Reduction Neutralization Test Assay for Measuring SARS-CoV-2 Neutralizing Antibodies. *Curr Protoc Immunol* **131**, e116 (2020).
29. V. V. Edara *et al.*, Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. *Cell Host Microbe* **29**, 516-521.e513 (2021).
30. V. V. Edara *et al.*, Infection and Vaccine-Induced Neutralizing-Antibody Responses to the SARS-CoV-2 B.1.617 Variants. *N Engl J Med* **385**, 664-666 (2021).
31. L. C. Katzelnick *et al.*, Viridot: An automated virus plaque (immunofocus) counter for the measurement of serological neutralizing responses with application to dengue virus. *PLoS Negl Trop Dis* **12**, e0006862 (2018).

Tables

Table 1: Sample characteristics

	Age ¹ (range)	Sex	Days post exposure (range or protocol specified maximum deviation)
Placebo	33 (26-39)	60% female	14 (11-17) ²
1 ug NDV-HXP-S	39 (32-45)	60% female	14 (11-17) ²
1 ug NDV-HXP-S + ODN1018	37 (29-49)	80% female	14 (11-17) ²
3 ug NDV-HXP-S	34 (25-44)	57.1 % female	14 (11-17) ²
3 ug NDV-HXP-S + ODN1018	37 (31-42)	48.6 % female	14 (11-17) ²
10 ug NDV-HXP-S	32 (27-42)	60% female	14 (11-17) ²
BNT162b2 (Pfizer)	39 (23-48)	80% female	15 (10-20) ³
Healthy convalescent	39 (26-59)	55.6% female	29.5 (14-49) ⁴

¹median

²post 2nd dose, target interval plus maximum protocol deviation in parenthesis

³post 2nd dose for mRNA vaccinees, median plus range

⁴post-PCR confirmation for convalescent individuals , median plus range

Figure Legends

Figure 1: Neutralizing activity of vaccinee and convalescent sera against wild type SARS-CoV-2 and the Delta and Beta variants. Neutralization was measured against wild type SARS-CoV-2 strain USA-WA01/2020 (A), a Delta (B.1.617.2) isolate (B) and a Beta (B.1.351) isolate (C) in a microneutralization assay with authentic SARS-CoV-2. For vaccine groups N=35, 20 individuals were included in the BNT162b2 group and sera from 18 individuals were included in the HCS group. The exception is the 3µg group where only 34 samples were tested in B and only 31 in C, the 1ug and 1 ug + ODN1018 groups in C where n=34 and the placebo group in C where n=33 due to a lack of sample volume. Bars show geometric mean titer (GMT), error bars indicate standard deviation of the GMT. The dotted line indicates the limit of detection; values below the limit of detection were assigned a value of half of the limit of detection.

Figure 2: Binding activity of vaccinee and convalescent sera against wild type and variant spike proteins. In A, binding to wild type spike protein was assessed using the SeroKlir Kantaro Semi-Quantitative SARS-CoV-2 IgG Antibody Kit . In B, a research grade ELISA was used to assess binding to wild type as well as variant spike proteins. For vaccine groups N=35, 20 individuals were included in the BNT162b2 group and sera from 18 individuals were included in the HCS group. The exception was the BNT162b2 group for which N was 18 in A. Bars show geometric mean titers (GMT), error bars indicate standard deviation of

the GMT. The dotted line indicates the limit of detection; values below the limit of detection were assigned a value of half of the limit of detection.

Figure 3: Ratios of binding to neutralizing activity. **A** shows ratios between binding and neutralizing activity for wild type SARS-CoV-2. Binding was analyzed using a research grade ELISA (Figure 2B) and neutralization was assessed using a microneutralization assay (Figure 1A). **B** shows a subset of samples analyzed blindly in an independent laboratory using the MesoScale Discovery platform for binding and an FRNT₅₀ assay for neutralization. **C** shows ratios for Delta using Delta binding and neutralization data (from Figures 2B and 1B) and **D** shows ratios for Beta using Beta binding and neutralization data (from Figures 2B and 1C). Geometric mean ratios are shown; error bars indicate standard deviation of the GMR. For vaccine groups N=35, 20 individuals were included in the BNT162b2 group and sera from 18 individuals were included in the HCS group. The exception was **B** for which a subset of 19 NDV-HXP-S samples was tested and the N for BNT162b2 and HCS was 12. In addition, in **C** the N for the 3 ug group is 34 and in **D** the N for the 1ug and 1ug+ODN1018 is 34 and for the 3 ug group it is 31 due to the lack of neutralization data. Statistical analysis was performed using a one-way ANOVA corrected for multiple comparisons. Statistical significant differences are indicated in the figure.

Figure 4: Binding activity of vaccine and convalescent sera to RBD, NTD, and S2. **A** shows binding of the serum panel to RBD, **B** shows binding to NTD and **C** shows binding to recombinant S2 protein. For vaccine groups N=35, 20 individuals were included in the BNT162b2 group and sera from 18 individuals were included in the HCS group. Bars show geometric mean titers (GMT), error bars indicate standard deviation of the GMT. The dotted line indicates the limit of detection, values below the limit of detection were assigned a value of half of the limit of detection.

A Neutralization of SARS-CoV-2
USA-WA01/2020 (wild type)

B Neutralization of SARS-CoV-2
B.1.617.2 (Delta)

C Neutralization of SARS-CoV-2
B.1.351 (Beta)

A

Wild type spike binding (Kantaro assay)

B

Binding to wild type and variant spike proteins

A Ratio of binding to neutralizing activity
(wild type SARS-CoV-2)

B Ratio of binding to neutralizing activity
(wild type SARS-CoV-2, 2nd laboratory)

C Ratio of binding to neutralizing activity
(B.1.617.2/Delta)

D Ratio of binding to neutralizing activity
(B.1.351/Beta)

A**RBD reactivity** **B****NTD reactivity** **C****S2 reactivity**